| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cardiovascular Diseases | 82 | 2026 | 2121 | 8.810 |
Why?
|
| Atherosclerosis | 73 | 2026 | 948 | 8.590 |
Why?
|
| Troponin T | 47 | 2025 | 259 | 5.340 |
Why?
|
| Heart Failure | 55 | 2026 | 2332 | 4.660 |
Why?
|
| Coronary Artery Disease | 31 | 2024 | 887 | 4.090 |
Why?
|
| Carotid Intima-Media Thickness | 20 | 2023 | 77 | 3.920 |
Why?
|
| Natriuretic Peptide, Brain | 30 | 2025 | 325 | 3.910 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 36 | 2026 | 744 | 3.580 |
Why?
|
| Biomarkers | 91 | 2026 | 3385 | 3.480 |
Why?
|
| Risk Assessment | 70 | 2026 | 3711 | 3.460 |
Why?
|
| Coronary Disease | 24 | 2023 | 624 | 3.130 |
Why?
|
| Hypertension | 24 | 2025 | 1356 | 3.070 |
Why?
|
| Plaque, Atherosclerotic | 16 | 2023 | 150 | 2.990 |
Why?
|
| Risk Factors | 139 | 2026 | 11074 | 2.950 |
Why?
|
| Peptide Fragments | 26 | 2025 | 687 | 2.660 |
Why?
|
| Cholesterol, LDL | 27 | 2026 | 604 | 2.650 |
Why?
|
| Carotid Artery Diseases | 12 | 2020 | 130 | 2.590 |
Why?
|
| Dyslipidemias | 13 | 2026 | 256 | 2.560 |
Why?
|
| Hypolipidemic Agents | 11 | 2026 | 202 | 2.390 |
Why?
|
| Myocardial Infarction | 21 | 2025 | 999 | 2.330 |
Why?
|
| Diabetes Mellitus | 19 | 2025 | 889 | 2.250 |
Why?
|
| Proprotein Convertase 9 | 11 | 2024 | 108 | 2.210 |
Why?
|
| Blood Pressure | 19 | 2024 | 1345 | 1.980 |
Why?
|
| Humans | 305 | 2026 | 131163 | 1.950 |
Why?
|
| Hyperlipoproteinemia Type II | 6 | 2026 | 119 | 1.930 |
Why?
|
| Peripheral Arterial Disease | 17 | 2026 | 326 | 1.830 |
Why?
|
| Vascular Stiffness | 7 | 2022 | 76 | 1.830 |
Why?
|
| Carotid Arteries | 7 | 2022 | 124 | 1.810 |
Why?
|
| Middle Aged | 160 | 2026 | 28601 | 1.670 |
Why?
|
| Anticholesteremic Agents | 7 | 2024 | 239 | 1.590 |
Why?
|
| Aged | 122 | 2026 | 21025 | 1.430 |
Why?
|
| Cholesterol | 14 | 2022 | 539 | 1.430 |
Why?
|
| Male | 180 | 2026 | 64957 | 1.330 |
Why?
|
| C-Reactive Protein | 19 | 2024 | 450 | 1.300 |
Why?
|
| Primary Prevention | 7 | 2024 | 183 | 1.300 |
Why?
|
| Obesity | 20 | 2026 | 2426 | 1.270 |
Why?
|
| Cholesterol, HDL | 6 | 2024 | 383 | 1.260 |
Why?
|
| United States | 80 | 2026 | 12072 | 1.250 |
Why?
|
| Stroke | 15 | 2024 | 1061 | 1.200 |
Why?
|
| Female | 173 | 2026 | 70963 | 1.180 |
Why?
|
| 1-Alkyl-2-acetylglycerophosphocholine Esterase | 9 | 2019 | 91 | 1.180 |
Why?
|
| Acute Coronary Syndrome | 6 | 2021 | 235 | 1.120 |
Why?
|
| Prospective Studies | 52 | 2026 | 6459 | 1.120 |
Why?
|
| Vascular Calcification | 4 | 2024 | 70 | 1.090 |
Why?
|
| Carotid Artery, Common | 5 | 2012 | 59 | 1.080 |
Why?
|
| Lipoprotein(a) | 9 | 2026 | 142 | 1.070 |
Why?
|
| Galectin 3 | 4 | 2024 | 32 | 1.060 |
Why?
|
| Incidence | 38 | 2026 | 3360 | 1.060 |
Why?
|
| Secondary Prevention | 3 | 2024 | 217 | 1.060 |
Why?
|
| Heart Diseases | 5 | 2019 | 499 | 1.060 |
Why?
|
| Preventive Health Services | 2 | 2018 | 59 | 1.030 |
Why?
|
| Prognosis | 33 | 2026 | 4886 | 0.940 |
Why?
|
| Practice Guidelines as Topic | 14 | 2026 | 1295 | 0.930 |
Why?
|
| Metabolic Syndrome | 7 | 2025 | 369 | 0.910 |
Why?
|
| Echocardiography | 8 | 2025 | 1125 | 0.870 |
Why?
|
| Atrial Fibrillation | 9 | 2024 | 738 | 0.860 |
Why?
|
| Image Interpretation, Computer-Assisted | 2 | 2016 | 229 | 0.850 |
Why?
|
| American Heart Association | 8 | 2026 | 343 | 0.850 |
Why?
|
| Carotid Artery, Internal | 3 | 2015 | 55 | 0.840 |
Why?
|
| Hyperlipidemias | 4 | 2025 | 185 | 0.830 |
Why?
|
| Carotid Stenosis | 5 | 2021 | 106 | 0.820 |
Why?
|
| Serine Proteinase Inhibitors | 3 | 2019 | 38 | 0.810 |
Why?
|
| Brain Ischemia | 5 | 2023 | 266 | 0.770 |
Why?
|
| Cardiology | 9 | 2023 | 514 | 0.770 |
Why?
|
| Ultrasonography | 6 | 2015 | 943 | 0.760 |
Why?
|
| Coronary Vessels | 5 | 2021 | 521 | 0.760 |
Why?
|
| Troponin | 4 | 2024 | 69 | 0.730 |
Why?
|
| Calcium | 6 | 2024 | 1010 | 0.730 |
Why?
|
| Body Mass Index | 16 | 2025 | 1717 | 0.720 |
Why?
|
| Tunica Intima | 3 | 2011 | 61 | 0.720 |
Why?
|
| Inflammation | 7 | 2022 | 1489 | 0.700 |
Why?
|
| Clinical Trials as Topic | 10 | 2024 | 1129 | 0.690 |
Why?
|
| Chromosomes, Human, Pair 9 | 5 | 2012 | 109 | 0.680 |
Why?
|
| Dicarboxylic Acids | 1 | 2021 | 37 | 0.670 |
Why?
|
| Antihypertensive Agents | 7 | 2024 | 414 | 0.660 |
Why?
|
| Vascular Diseases | 3 | 2022 | 146 | 0.660 |
Why?
|
| Lipid Metabolism | 1 | 2024 | 387 | 0.660 |
Why?
|
| Platelet Aggregation Inhibitors | 7 | 2021 | 267 | 0.660 |
Why?
|
| Time Factors | 29 | 2026 | 6196 | 0.650 |
Why?
|
| Sleep Apnea, Obstructive | 3 | 2023 | 245 | 0.650 |
Why?
|
| Percutaneous Coronary Intervention | 2 | 2021 | 299 | 0.630 |
Why?
|
| Lipids | 9 | 2023 | 569 | 0.620 |
Why?
|
| Triglycerides | 9 | 2025 | 602 | 0.620 |
Why?
|
| Predictive Value of Tests | 17 | 2024 | 2304 | 0.610 |
Why?
|
| Cognition Disorders | 2 | 2021 | 556 | 0.610 |
Why?
|
| Protein Precursors | 4 | 2021 | 140 | 0.610 |
Why?
|
| General Practitioners | 1 | 2019 | 18 | 0.590 |
Why?
|
| Troponin I | 5 | 2024 | 122 | 0.590 |
Why?
|
| Hospitalization | 13 | 2024 | 1950 | 0.590 |
Why?
|
| Magnetic Resonance Imaging | 17 | 2023 | 3763 | 0.580 |
Why?
|
| Adult | 54 | 2026 | 31282 | 0.580 |
Why?
|
| Population Surveillance | 2 | 2021 | 396 | 0.570 |
Why?
|
| Heterozygote | 1 | 2021 | 737 | 0.570 |
Why?
|
| Fatty Acids | 1 | 2021 | 377 | 0.570 |
Why?
|
| Cohort Studies | 29 | 2025 | 5063 | 0.560 |
Why?
|
| Renal Insufficiency, Chronic | 6 | 2022 | 853 | 0.550 |
Why?
|
| Myocardium | 4 | 2019 | 852 | 0.530 |
Why?
|
| Phospholipases A | 5 | 2014 | 31 | 0.530 |
Why?
|
| Blood Pressure Determination | 2 | 2016 | 118 | 0.530 |
Why?
|
| Education | 1 | 2018 | 112 | 0.520 |
Why?
|
| Aged, 80 and over | 28 | 2026 | 6797 | 0.510 |
Why?
|
| Dementia | 2 | 2024 | 436 | 0.510 |
Why?
|
| Reproducibility of Results | 14 | 2022 | 2904 | 0.510 |
Why?
|
| Fatty Acids, Omega-3 | 3 | 2021 | 80 | 0.510 |
Why?
|
| Hypertriglyceridemia | 4 | 2025 | 117 | 0.500 |
Why?
|
| Echocardiography, Three-Dimensional | 2 | 2016 | 64 | 0.500 |
Why?
|
| Life Expectancy | 2 | 2025 | 63 | 0.490 |
Why?
|
| Thrombosis | 1 | 2021 | 499 | 0.490 |
Why?
|
| Coronary Artery Bypass | 10 | 2013 | 515 | 0.490 |
Why?
|
| Women's Health | 1 | 2017 | 134 | 0.480 |
Why?
|
| Lipoproteins, HDL | 3 | 2024 | 97 | 0.480 |
Why?
|
| Proportional Hazards Models | 17 | 2025 | 1410 | 0.470 |
Why?
|
| Image Enhancement | 1 | 2016 | 159 | 0.460 |
Why?
|
| Imaging, Three-Dimensional | 2 | 2015 | 371 | 0.460 |
Why?
|
| Follow-Up Studies | 24 | 2025 | 5196 | 0.460 |
Why?
|
| Health Status Disparities | 2 | 2024 | 282 | 0.450 |
Why?
|
| Disease Management | 3 | 2017 | 558 | 0.450 |
Why?
|
| Income | 3 | 2026 | 138 | 0.450 |
Why?
|
| Hypoxia | 2 | 2023 | 247 | 0.450 |
Why?
|
| Treatment Outcome | 30 | 2026 | 12936 | 0.450 |
Why?
|
| Diabetes Mellitus, Type 2 | 4 | 2023 | 1459 | 0.440 |
Why?
|
| Sensitivity and Specificity | 11 | 2019 | 2085 | 0.440 |
Why?
|
| Continuous Positive Airway Pressure | 1 | 2015 | 63 | 0.440 |
Why?
|
| Postprandial Period | 1 | 2015 | 93 | 0.430 |
Why?
|
| Ventricular Function, Left | 4 | 2025 | 549 | 0.430 |
Why?
|
| Hypercholesterolemia | 5 | 2021 | 230 | 0.430 |
Why?
|
| Oligonucleotides | 1 | 2015 | 94 | 0.420 |
Why?
|
| Leg | 5 | 2023 | 118 | 0.420 |
Why?
|
| Football | 5 | 2014 | 39 | 0.420 |
Why?
|
| Aspirin | 5 | 2021 | 211 | 0.420 |
Why?
|
| Oligonucleotides, Antisense | 1 | 2015 | 70 | 0.420 |
Why?
|
| Prevalence | 15 | 2025 | 2701 | 0.420 |
Why?
|
| Tunica Media | 2 | 2011 | 15 | 0.420 |
Why?
|
| Veterans | 6 | 2025 | 1763 | 0.410 |
Why?
|
| Practice Patterns, Physicians' | 5 | 2026 | 789 | 0.410 |
Why?
|
| Dietary Fats | 1 | 2015 | 278 | 0.400 |
Why?
|
| Ankle Brachial Index | 6 | 2022 | 40 | 0.400 |
Why?
|
| Clinical Competence | 2 | 2019 | 1050 | 0.370 |
Why?
|
| Polymorphism, Single Nucleotide | 13 | 2013 | 2833 | 0.370 |
Why?
|
| Peripheral Vascular Diseases | 3 | 2011 | 73 | 0.370 |
Why?
|
| Platelet Aggregation | 2 | 2011 | 100 | 0.370 |
Why?
|
| Pulse Wave Analysis | 4 | 2022 | 48 | 0.370 |
Why?
|
| Ultrasonography, Doppler, Pulsed | 1 | 2012 | 20 | 0.360 |
Why?
|
| Mortality | 4 | 2024 | 264 | 0.360 |
Why?
|
| Sleep Apnea Syndromes | 2 | 2023 | 96 | 0.360 |
Why?
|
| Ultrasonography, Doppler | 3 | 2014 | 187 | 0.360 |
Why?
|
| Goals | 4 | 2020 | 126 | 0.350 |
Why?
|
| Apolipoprotein C-III | 3 | 2025 | 46 | 0.350 |
Why?
|
| Cause of Death | 5 | 2025 | 506 | 0.350 |
Why?
|
| Veterans Health | 3 | 2025 | 170 | 0.340 |
Why?
|
| Peroxidase | 3 | 2008 | 63 | 0.340 |
Why?
|
| Biological Transport | 2 | 2024 | 329 | 0.330 |
Why?
|
| Vasa Vasorum | 1 | 2010 | 1 | 0.330 |
Why?
|
| Prediabetic State | 2 | 2024 | 68 | 0.330 |
Why?
|
| Cardiomyopathies | 4 | 2019 | 514 | 0.330 |
Why?
|
| Postoperative Care | 2 | 2025 | 294 | 0.330 |
Why?
|
| RNA, Small Interfering | 2 | 2024 | 664 | 0.330 |
Why?
|
| Purinergic P2Y Receptor Antagonists | 3 | 2021 | 43 | 0.330 |
Why?
|
| Retirement | 4 | 2014 | 18 | 0.330 |
Why?
|
| Elasticity Imaging Techniques | 1 | 2013 | 161 | 0.330 |
Why?
|
| Nutrition Surveys | 4 | 2026 | 338 | 0.320 |
Why?
|
| Health Status Indicators | 1 | 2010 | 111 | 0.320 |
Why?
|
| Ezetimibe | 5 | 2019 | 93 | 0.310 |
Why?
|
| Phantoms, Imaging | 1 | 2011 | 142 | 0.310 |
Why?
|
| Residence Characteristics | 6 | 2024 | 295 | 0.310 |
Why?
|
| HIV Infections | 2 | 2020 | 2049 | 0.310 |
Why?
|
| Cholesterol Ester Transfer Proteins | 2 | 2024 | 39 | 0.300 |
Why?
|
| Cross-Sectional Studies | 12 | 2024 | 3829 | 0.300 |
Why?
|
| Galectins | 4 | 2024 | 24 | 0.300 |
Why?
|
| Risk Reduction Behavior | 3 | 2020 | 143 | 0.300 |
Why?
|
| Exercise | 4 | 2021 | 892 | 0.300 |
Why?
|
| Metabolomics | 2 | 2026 | 501 | 0.290 |
Why?
|
| Retrospective Studies | 25 | 2024 | 17753 | 0.290 |
Why?
|
| Severity of Illness Index | 13 | 2021 | 3061 | 0.290 |
Why?
|
| Platelet Activation | 1 | 2009 | 64 | 0.290 |
Why?
|
| ROC Curve | 5 | 2012 | 613 | 0.290 |
Why?
|
| Machine Learning | 2 | 2024 | 387 | 0.290 |
Why?
|
| Healthy Lifestyle | 2 | 2020 | 33 | 0.290 |
Why?
|
| Hypertrophy, Left Ventricular | 3 | 2022 | 108 | 0.280 |
Why?
|
| Stroke Volume | 5 | 2025 | 541 | 0.280 |
Why?
|
| Drug Costs | 2 | 2019 | 66 | 0.280 |
Why?
|
| Guideline Adherence | 8 | 2019 | 387 | 0.280 |
Why?
|
| Odds Ratio | 12 | 2019 | 1211 | 0.280 |
Why?
|
| Matrix Metalloproteinase 1 | 1 | 2008 | 23 | 0.270 |
Why?
|
| Eligibility Determination | 2 | 2019 | 38 | 0.270 |
Why?
|
| Lipoproteins | 4 | 2022 | 183 | 0.270 |
Why?
|
| Tissue Inhibitor of Metalloproteinase-1 | 1 | 2008 | 38 | 0.270 |
Why?
|
| Heart Transplantation | 2 | 2025 | 800 | 0.270 |
Why?
|
| Double-Blind Method | 8 | 2021 | 1626 | 0.260 |
Why?
|
| Sex Factors | 6 | 2017 | 1356 | 0.260 |
Why?
|
| Femoral Artery | 4 | 2023 | 134 | 0.260 |
Why?
|
| Comorbidity | 7 | 2024 | 1595 | 0.260 |
Why?
|
| Cognitive Dysfunction | 2 | 2024 | 338 | 0.260 |
Why?
|
| Registries | 6 | 2018 | 1634 | 0.260 |
Why?
|
| Social Class | 2 | 2026 | 214 | 0.250 |
Why?
|
| Delivery of Health Care | 2 | 2025 | 689 | 0.250 |
Why?
|
| Intermittent Claudication | 3 | 2023 | 48 | 0.250 |
Why?
|
| Global Health | 2 | 2025 | 626 | 0.250 |
Why?
|
| Inflammation Mediators | 2 | 2020 | 226 | 0.250 |
Why?
|
| Ischemia | 2 | 2020 | 359 | 0.250 |
Why?
|
| Metformin | 2 | 2026 | 174 | 0.250 |
Why?
|
| Obesity, Morbid | 3 | 2022 | 232 | 0.240 |
Why?
|
| Gastrointestinal Hemorrhage | 2 | 2021 | 239 | 0.240 |
Why?
|
| Life Style | 5 | 2026 | 456 | 0.240 |
Why?
|
| Apolipoprotein A-I | 2 | 2011 | 80 | 0.230 |
Why?
|
| Heart Ventricles | 3 | 2021 | 749 | 0.230 |
Why?
|
| Cognition | 3 | 2024 | 829 | 0.230 |
Why?
|
| Hypertension, Pulmonary | 2 | 2021 | 457 | 0.230 |
Why?
|
| Postoperative Complications | 6 | 2025 | 3147 | 0.230 |
Why?
|
| Gulf War | 1 | 2025 | 9 | 0.230 |
Why?
|
| Heart Septum | 1 | 2005 | 41 | 0.230 |
Why?
|
| Solvents | 1 | 2005 | 39 | 0.230 |
Why?
|
| United States Department of Veterans Affairs | 6 | 2021 | 729 | 0.220 |
Why?
|
| Genetic Testing | 3 | 2026 | 1106 | 0.220 |
Why?
|
| Receptors, LDL | 2 | 2026 | 106 | 0.220 |
Why?
|
| Hyperlipoproteinemia Type I | 1 | 2025 | 11 | 0.220 |
Why?
|
| Adrenergic beta-Antagonists | 2 | 2025 | 216 | 0.220 |
Why?
|
| Pancreatitis | 2 | 2025 | 139 | 0.220 |
Why?
|
| Apolipoproteins B | 3 | 2026 | 142 | 0.220 |
Why?
|
| Heart-Assist Devices | 2 | 2024 | 1020 | 0.220 |
Why?
|
| Randomized Controlled Trials as Topic | 4 | 2025 | 1267 | 0.220 |
Why?
|
| Adiponectin | 1 | 2025 | 123 | 0.220 |
Why?
|
| Adipokines | 1 | 2025 | 119 | 0.220 |
Why?
|
| Hypoglycemic Agents | 2 | 2026 | 480 | 0.210 |
Why?
|
| Hospital Mortality | 7 | 2025 | 1064 | 0.210 |
Why?
|
| Age Factors | 8 | 2025 | 2825 | 0.210 |
Why?
|
| Calcinosis | 3 | 2014 | 180 | 0.210 |
Why?
|
| Echocardiography, Stress | 2 | 2020 | 19 | 0.210 |
Why?
|
| Protective Factors | 3 | 2021 | 91 | 0.210 |
Why?
|
| Angioplasty, Balloon, Coronary | 1 | 2005 | 161 | 0.210 |
Why?
|
| Erythrocyte Transfusion | 1 | 2025 | 146 | 0.210 |
Why?
|
| Waist Circumference | 2 | 2014 | 94 | 0.210 |
Why?
|
| Renin-Angiotensin System | 2 | 2024 | 104 | 0.210 |
Why?
|
| Clinical Decision-Making | 4 | 2021 | 314 | 0.210 |
Why?
|
| Blood Pressure Monitoring, Ambulatory | 1 | 2024 | 52 | 0.210 |
Why?
|
| Leptin | 1 | 2025 | 218 | 0.200 |
Why?
|
| Occupational Exposure | 1 | 2025 | 135 | 0.200 |
Why?
|
| Ethanol | 1 | 2005 | 170 | 0.200 |
Why?
|
| Dioxygenases | 1 | 2024 | 69 | 0.200 |
Why?
|
| Cardiomyopathy, Hypertrophic | 1 | 2005 | 161 | 0.200 |
Why?
|
| Cardiac Resynchronization Therapy | 1 | 2024 | 49 | 0.200 |
Why?
|
| Cardiologists | 1 | 2023 | 26 | 0.200 |
Why?
|
| Confidence Intervals | 4 | 2017 | 272 | 0.200 |
Why?
|
| Physicians, Primary Care | 1 | 2024 | 100 | 0.200 |
Why?
|
| Genome-Wide Association Study | 6 | 2013 | 1833 | 0.200 |
Why?
|
| Matrix Metalloproteinase 2 | 1 | 2023 | 86 | 0.200 |
Why?
|
| Heart | 3 | 2024 | 650 | 0.190 |
Why?
|
| Thromboembolism | 1 | 2004 | 93 | 0.190 |
Why?
|
| Phenotype | 8 | 2024 | 4497 | 0.190 |
Why?
|
| Surgical Procedures, Operative | 1 | 2025 | 225 | 0.190 |
Why?
|
| Young Adult | 7 | 2024 | 10103 | 0.190 |
Why?
|
| Simvastatin | 4 | 2015 | 76 | 0.190 |
Why?
|
| Cardiovascular System | 1 | 2024 | 97 | 0.190 |
Why?
|
| Smoking Cessation | 2 | 2025 | 191 | 0.190 |
Why?
|
| Genetic Predisposition to Disease | 9 | 2026 | 3436 | 0.190 |
Why?
|
| Drug Monitoring | 3 | 2021 | 292 | 0.190 |
Why?
|
| Antibodies, Monoclonal | 2 | 2020 | 981 | 0.190 |
Why?
|
| Thrombolytic Therapy | 1 | 2004 | 191 | 0.180 |
Why?
|
| Texas | 10 | 2024 | 3686 | 0.180 |
Why?
|
| Blood Volume | 2 | 2020 | 73 | 0.180 |
Why?
|
| Anterior Wall Myocardial Infarction | 1 | 2022 | 11 | 0.180 |
Why?
|
| Venous Thrombosis | 1 | 2004 | 164 | 0.180 |
Why?
|
| Thiazolidinediones | 1 | 2002 | 81 | 0.180 |
Why?
|
| Forecasting | 2 | 2018 | 351 | 0.180 |
Why?
|
| Hypotension | 1 | 2024 | 187 | 0.180 |
Why?
|
| Education, Medical, Graduate | 2 | 2018 | 554 | 0.180 |
Why?
|
| Anemia | 1 | 2025 | 354 | 0.180 |
Why?
|
| Thigh | 3 | 2022 | 50 | 0.170 |
Why?
|
| Smoking | 4 | 2025 | 932 | 0.170 |
Why?
|
| Surveys and Questionnaires | 6 | 2019 | 4066 | 0.170 |
Why?
|
| Linear Models | 6 | 2017 | 688 | 0.170 |
Why?
|
| Circadian Rhythm | 1 | 2024 | 327 | 0.170 |
Why?
|
| Suicide | 1 | 2024 | 208 | 0.170 |
Why?
|
| Obesity, Metabolically Benign | 1 | 2021 | 3 | 0.170 |
Why?
|
| Contrast Media | 4 | 2019 | 474 | 0.170 |
Why?
|
| Healthcare Disparities | 2 | 2017 | 523 | 0.170 |
Why?
|
| Military Medicine | 1 | 2021 | 52 | 0.170 |
Why?
|
| Blood Proteins | 4 | 2024 | 143 | 0.170 |
Why?
|
| Muscle, Skeletal | 4 | 2023 | 981 | 0.170 |
Why?
|
| Preoperative Care | 4 | 2012 | 358 | 0.170 |
Why?
|
| Consensus | 2 | 2021 | 512 | 0.160 |
Why?
|
| Dehydroepiandrosterone Sulfate | 1 | 2020 | 19 | 0.160 |
Why?
|
| Venous Thromboembolism | 2 | 2014 | 195 | 0.160 |
Why?
|
| Fish Oils | 1 | 2021 | 82 | 0.160 |
Why?
|
| Shock, Septic | 1 | 2022 | 150 | 0.160 |
Why?
|
| Albuminuria | 2 | 2022 | 107 | 0.160 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2024 | 597 | 0.160 |
Why?
|
| Data Collection | 1 | 2022 | 370 | 0.160 |
Why?
|
| Patient Selection | 3 | 2019 | 729 | 0.160 |
Why?
|
| Health Knowledge, Attitudes, Practice | 3 | 2016 | 919 | 0.160 |
Why?
|
| Regional Blood Flow | 1 | 2020 | 191 | 0.160 |
Why?
|
| Natriuretic Peptides | 1 | 2019 | 9 | 0.160 |
Why?
|
| Tobacco Products | 1 | 2020 | 60 | 0.150 |
Why?
|
| Health Status | 2 | 2025 | 378 | 0.150 |
Why?
|
| Vaping | 1 | 2020 | 31 | 0.150 |
Why?
|
| Repressor Proteins | 1 | 2024 | 760 | 0.150 |
Why?
|
| Retinal Vessels | 1 | 2020 | 48 | 0.150 |
Why?
|
| Patient Care Management | 1 | 2020 | 61 | 0.150 |
Why?
|
| Perfusion | 2 | 2023 | 209 | 0.150 |
Why?
|
| Kaplan-Meier Estimate | 6 | 2020 | 1071 | 0.150 |
Why?
|
| Electronic Nicotine Delivery Systems | 1 | 2020 | 60 | 0.150 |
Why?
|
| Risk | 5 | 2014 | 726 | 0.150 |
Why?
|
| Microvessels | 1 | 2020 | 58 | 0.150 |
Why?
|
| P-Selectin | 2 | 2010 | 69 | 0.150 |
Why?
|
| Logistic Models | 9 | 2016 | 1797 | 0.150 |
Why?
|
| India | 1 | 2020 | 234 | 0.150 |
Why?
|
| Drug Prescriptions | 3 | 2018 | 237 | 0.150 |
Why?
|
| Cerebrovascular Disorders | 2 | 2018 | 111 | 0.150 |
Why?
|
| Blood Flow Velocity | 1 | 2020 | 417 | 0.150 |
Why?
|
| ATP Binding Cassette Transporter 1 | 1 | 2018 | 16 | 0.150 |
Why?
|
| Oxygen Inhalation Therapy | 1 | 2019 | 88 | 0.140 |
Why?
|
| Artificial Intelligence | 2 | 2020 | 369 | 0.140 |
Why?
|
| Renal Insufficiency | 3 | 2011 | 259 | 0.140 |
Why?
|
| Walking | 1 | 2020 | 230 | 0.140 |
Why?
|
| Magnetic Resonance Imaging, Cine | 1 | 2019 | 176 | 0.140 |
Why?
|
| Antibodies, Monoclonal, Humanized | 2 | 2020 | 570 | 0.140 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 3 | 2012 | 214 | 0.140 |
Why?
|
| Behavior Therapy | 1 | 2021 | 273 | 0.140 |
Why?
|
| Treatment Failure | 2 | 2018 | 351 | 0.140 |
Why?
|
| Eicosapentaenoic Acid | 1 | 2019 | 82 | 0.140 |
Why?
|
| Renal Replacement Therapy | 1 | 2020 | 172 | 0.140 |
Why?
|
| Endarterectomy, Carotid | 2 | 2015 | 75 | 0.140 |
Why?
|
| Death, Sudden, Cardiac | 1 | 2020 | 268 | 0.140 |
Why?
|
| Decision Support Techniques | 2 | 2019 | 293 | 0.140 |
Why?
|
| Exercise Therapy | 3 | 2021 | 173 | 0.130 |
Why?
|
| Attitude of Health Personnel | 2 | 2016 | 707 | 0.130 |
Why?
|
| Sick Sinus Syndrome | 1 | 2018 | 17 | 0.130 |
Why?
|
| Apolipoproteins E | 1 | 2018 | 187 | 0.130 |
Why?
|
| Mammography | 1 | 2018 | 122 | 0.130 |
Why?
|
| Vena Cava, Superior | 1 | 2018 | 58 | 0.130 |
Why?
|
| Monitoring, Physiologic | 1 | 2019 | 376 | 0.130 |
Why?
|
| Education, Medical, Continuing | 2 | 2016 | 132 | 0.130 |
Why?
|
| Inpatients | 3 | 2024 | 562 | 0.130 |
Why?
|
| Phospholipases A2 | 2 | 2007 | 31 | 0.130 |
Why?
|
| Glomerular Filtration Rate | 4 | 2022 | 566 | 0.130 |
Why?
|
| Myocardial Revascularization | 3 | 2021 | 100 | 0.130 |
Why?
|
| Hypogonadism | 1 | 2021 | 299 | 0.130 |
Why?
|
| Physicians | 1 | 2023 | 635 | 0.120 |
Why?
|
| Societies, Medical | 2 | 2025 | 798 | 0.120 |
Why?
|
| Femoral Vein | 1 | 2016 | 42 | 0.120 |
Why?
|
| Serine Endopeptidases | 1 | 2017 | 197 | 0.120 |
Why?
|
| Endothelium, Vascular | 3 | 2013 | 468 | 0.120 |
Why?
|
| Oxygen | 1 | 2019 | 548 | 0.120 |
Why?
|
| Alcohol Dehydrogenase | 1 | 2016 | 18 | 0.120 |
Why?
|
| Cell-Derived Microparticles | 1 | 2016 | 26 | 0.120 |
Why?
|
| DNA-Binding Proteins | 1 | 2024 | 1939 | 0.120 |
Why?
|
| Cystatin C | 1 | 2016 | 70 | 0.120 |
Why?
|
| Longitudinal Studies | 5 | 2020 | 1490 | 0.120 |
Why?
|
| Propensity Score | 3 | 2012 | 271 | 0.110 |
Why?
|
| Drug Therapy, Combination | 5 | 2021 | 1173 | 0.110 |
Why?
|
| Inservice Training | 1 | 2016 | 56 | 0.110 |
Why?
|
| Up-Regulation | 4 | 2020 | 825 | 0.110 |
Why?
|
| Survival Rate | 5 | 2024 | 2114 | 0.110 |
Why?
|
| Testosterone | 1 | 2021 | 531 | 0.110 |
Why?
|
| Fibrinolytic Agents | 3 | 2020 | 182 | 0.110 |
Why?
|
| Endpoint Determination | 2 | 2007 | 58 | 0.110 |
Why?
|
| Pacemaker, Artificial | 1 | 2018 | 193 | 0.110 |
Why?
|
| Lower Extremity | 2 | 2022 | 185 | 0.110 |
Why?
|
| Amino Acids | 1 | 2018 | 566 | 0.110 |
Why?
|
| Fenofibrate | 2 | 2013 | 59 | 0.110 |
Why?
|
| Multivariate Analysis | 5 | 2021 | 1378 | 0.110 |
Why?
|
| Internship and Residency | 2 | 2018 | 1223 | 0.110 |
Why?
|
| Diabetes Complications | 1 | 2016 | 197 | 0.110 |
Why?
|
| Healthy Volunteers | 1 | 2015 | 154 | 0.110 |
Why?
|
| Fibrosis | 3 | 2022 | 429 | 0.110 |
Why?
|
| Fellowships and Scholarships | 1 | 2018 | 327 | 0.110 |
Why?
|
| Chemokine CCL5 | 2 | 2013 | 53 | 0.100 |
Why?
|
| Heptanoic Acids | 3 | 2014 | 79 | 0.100 |
Why?
|
| Occupations | 1 | 2014 | 17 | 0.100 |
Why?
|
| Pilot Projects | 2 | 2016 | 1445 | 0.100 |
Why?
|
| Ambulatory Care Facilities | 1 | 2016 | 231 | 0.100 |
Why?
|
| Heart Valve Prosthesis Implantation | 2 | 2009 | 425 | 0.100 |
Why?
|
| Hyperglycemia | 2 | 2013 | 234 | 0.100 |
Why?
|
| Thiophenes | 1 | 2014 | 69 | 0.100 |
Why?
|
| Athletes | 1 | 2014 | 77 | 0.100 |
Why?
|
| Liver | 1 | 2021 | 1796 | 0.100 |
Why?
|
| Ceruloplasmin | 1 | 2013 | 13 | 0.100 |
Why?
|
| Cardiovascular Agents | 2 | 2024 | 88 | 0.100 |
Why?
|
| Down-Regulation | 1 | 2015 | 645 | 0.100 |
Why?
|
| Acetates | 1 | 2014 | 77 | 0.100 |
Why?
|
| Pandemics | 1 | 2020 | 1118 | 0.100 |
Why?
|
| Prescription Drugs | 1 | 2014 | 54 | 0.100 |
Why?
|
| Combined Modality Therapy | 3 | 2021 | 1216 | 0.100 |
Why?
|
| Alcohol Drinking | 1 | 2016 | 341 | 0.100 |
Why?
|
| Brain Infarction | 1 | 2013 | 28 | 0.100 |
Why?
|
| Diet Therapy | 1 | 2013 | 40 | 0.100 |
Why?
|
| Neck | 1 | 2014 | 140 | 0.100 |
Why?
|
| Pyrroles | 3 | 2014 | 188 | 0.100 |
Why?
|
| Evidence-Based Medicine | 1 | 2016 | 645 | 0.090 |
Why?
|
| Adenosine Diphosphate | 2 | 2011 | 48 | 0.090 |
Why?
|
| Arachidonic Acid | 2 | 2011 | 52 | 0.090 |
Why?
|
| Algorithms | 4 | 2016 | 1680 | 0.090 |
Why?
|
| Leukoencephalopathies | 1 | 2013 | 63 | 0.090 |
Why?
|
| Curriculum | 1 | 2018 | 798 | 0.090 |
Why?
|
| Indoles | 1 | 2014 | 200 | 0.090 |
Why?
|
| Image Processing, Computer-Assisted | 2 | 2014 | 587 | 0.090 |
Why?
|
| Endothelial Cells | 1 | 2016 | 523 | 0.090 |
Why?
|
| Piperazines | 1 | 2014 | 265 | 0.090 |
Why?
|
| Transcription Factor 7-Like 2 Protein | 1 | 2012 | 25 | 0.090 |
Why?
|
| Interleukin-6 | 2 | 2024 | 412 | 0.090 |
Why?
|
| Heart Valves | 2 | 2010 | 52 | 0.090 |
Why?
|
| Death | 1 | 2012 | 78 | 0.090 |
Why?
|
| Antiretroviral Therapy, Highly Active | 1 | 2013 | 256 | 0.090 |
Why?
|
| Lipoproteins, LDL | 1 | 2012 | 119 | 0.090 |
Why?
|
| Area Under Curve | 2 | 2012 | 304 | 0.090 |
Why?
|
| Breast Neoplasms | 1 | 2024 | 2602 | 0.090 |
Why?
|
| Administration, Oral | 2 | 2025 | 711 | 0.080 |
Why?
|
| Epidemiologic Methods | 1 | 2011 | 91 | 0.080 |
Why?
|
| Muscles | 1 | 2011 | 197 | 0.080 |
Why?
|
| Chromosomes, Human, Pair 4 | 1 | 2011 | 53 | 0.080 |
Why?
|
| Vasodilator Agents | 2 | 2022 | 197 | 0.080 |
Why?
|
| Platelet Function Tests | 1 | 2011 | 37 | 0.080 |
Why?
|
| Reference Values | 4 | 2017 | 676 | 0.080 |
Why?
|
| Pravastatin | 2 | 2008 | 22 | 0.080 |
Why?
|
| Mutation | 1 | 2004 | 6099 | 0.080 |
Why?
|
| Cost-Benefit Analysis | 2 | 2019 | 555 | 0.080 |
Why?
|
| Vasculitis | 1 | 2011 | 47 | 0.080 |
Why?
|
| Early Diagnosis | 1 | 2011 | 195 | 0.080 |
Why?
|
| Cardiac Surgical Procedures | 2 | 2010 | 1168 | 0.080 |
Why?
|
| Socioeconomic Factors | 2 | 2026 | 915 | 0.080 |
Why?
|
| Behavioral Risk Factor Surveillance System | 2 | 2020 | 51 | 0.080 |
Why?
|
| Sex Characteristics | 1 | 2012 | 323 | 0.080 |
Why?
|
| ABO Blood-Group System | 1 | 2010 | 61 | 0.080 |
Why?
|
| Case-Control Studies | 3 | 2016 | 3359 | 0.080 |
Why?
|
| Overweight | 2 | 2025 | 387 | 0.080 |
Why?
|
| Intercellular Adhesion Molecule-1 | 1 | 2010 | 125 | 0.080 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2021 | 1618 | 0.080 |
Why?
|
| HIV-1 | 1 | 2013 | 490 | 0.070 |
Why?
|
| Apolipoproteins A | 1 | 2009 | 51 | 0.070 |
Why?
|
| Models, Genetic | 1 | 2012 | 749 | 0.070 |
Why?
|
| Stress, Mechanical | 1 | 2009 | 178 | 0.070 |
Why?
|
| Niacin | 3 | 2013 | 59 | 0.070 |
Why?
|
| Epinephrine | 1 | 2009 | 150 | 0.070 |
Why?
|
| Prasugrel Hydrochloride | 2 | 2021 | 23 | 0.070 |
Why?
|
| Diagnostic Imaging | 1 | 2010 | 305 | 0.070 |
Why?
|
| DNA | 1 | 2013 | 1399 | 0.070 |
Why?
|
| Weight Loss | 2 | 2021 | 538 | 0.070 |
Why?
|
| In Vitro Techniques | 1 | 2009 | 808 | 0.070 |
Why?
|
| Collagen | 1 | 2009 | 273 | 0.070 |
Why?
|
| Adolescent | 5 | 2024 | 20987 | 0.060 |
Why?
|
| Mass Screening | 2 | 2014 | 822 | 0.060 |
Why?
|
| Aging | 3 | 2022 | 1242 | 0.060 |
Why?
|
| Ventricular Dysfunction, Left | 2 | 2008 | 362 | 0.060 |
Why?
|
| Netherlands | 2 | 2020 | 55 | 0.060 |
Why?
|
| Acute Disease | 2 | 2022 | 1153 | 0.060 |
Why?
|
| Molecular Biology | 1 | 2007 | 66 | 0.060 |
Why?
|
| Arterial Occlusive Diseases | 1 | 2007 | 99 | 0.060 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 3 | 2016 | 787 | 0.060 |
Why?
|
| Gadolinium DTPA | 2 | 2019 | 46 | 0.060 |
Why?
|
| Patient Discharge | 2 | 2022 | 514 | 0.060 |
Why?
|
| Genotype | 4 | 2013 | 2595 | 0.060 |
Why?
|
| Databases, Factual | 2 | 2024 | 1240 | 0.060 |
Why?
|
| Single-Blind Method | 1 | 2025 | 238 | 0.060 |
Why?
|
| Tomography, Emission-Computed, Single-Photon | 1 | 2005 | 96 | 0.060 |
Why?
|
| Electrocardiography | 2 | 2021 | 970 | 0.060 |
Why?
|
| Lipid Peroxidation | 1 | 2005 | 93 | 0.050 |
Why?
|
| Defibrillators, Implantable | 2 | 2024 | 215 | 0.050 |
Why?
|
| Echocardiography, Doppler | 1 | 2005 | 158 | 0.050 |
Why?
|
| Smoke | 1 | 2025 | 79 | 0.050 |
Why?
|
| Allografts | 1 | 2025 | 220 | 0.050 |
Why?
|
| Educational Status | 1 | 2026 | 279 | 0.050 |
Why?
|
| Mississippi | 1 | 2024 | 35 | 0.050 |
Why?
|
| Thinness | 1 | 2025 | 71 | 0.050 |
Why?
|
| Cardiac Resynchronization Therapy Devices | 1 | 2024 | 17 | 0.050 |
Why?
|
| Enzyme Inhibitors | 1 | 2007 | 573 | 0.050 |
Why?
|
| Hemoglobins | 1 | 2025 | 286 | 0.050 |
Why?
|
| Massachusetts | 1 | 2024 | 122 | 0.050 |
Why?
|
| Dyspnea | 1 | 2005 | 159 | 0.050 |
Why?
|
| Electric Countershock | 1 | 2024 | 74 | 0.050 |
Why?
|
| Polymorphism, Genetic | 1 | 2007 | 776 | 0.050 |
Why?
|
| Angioplasty | 1 | 2004 | 63 | 0.050 |
Why?
|
| Mineralocorticoid Receptor Antagonists | 1 | 2024 | 45 | 0.050 |
Why?
|
| Animals | 4 | 2026 | 33912 | 0.050 |
Why?
|
| Anthropometry | 2 | 2014 | 187 | 0.050 |
Why?
|
| Particle Size | 1 | 2024 | 135 | 0.050 |
Why?
|
| Cardio-Renal Syndrome | 1 | 2024 | 24 | 0.050 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2006 | 301 | 0.050 |
Why?
|
| United Kingdom | 1 | 2024 | 267 | 0.050 |
Why?
|
| Mitral Valve | 1 | 2005 | 247 | 0.050 |
Why?
|
| Ventricular Fibrillation | 1 | 2003 | 51 | 0.050 |
Why?
|
| Interleukin-18 | 1 | 2023 | 75 | 0.050 |
Why?
|
| Angiotensin Receptor Antagonists | 1 | 2024 | 133 | 0.050 |
Why?
|
| Electrophysiologic Techniques, Cardiac | 1 | 2003 | 75 | 0.050 |
Why?
|
| Asymptomatic Diseases | 2 | 2014 | 77 | 0.050 |
Why?
|
| Chi-Square Distribution | 2 | 2017 | 563 | 0.050 |
Why?
|
| Proteomics | 1 | 2007 | 615 | 0.050 |
Why?
|
| Internationality | 1 | 2023 | 128 | 0.050 |
Why?
|
| Research Design | 1 | 2007 | 716 | 0.050 |
Why?
|
| Chest Pain | 1 | 2003 | 133 | 0.050 |
Why?
|
| DNA (Cytosine-5-)-Methyltransferases | 1 | 2024 | 156 | 0.050 |
Why?
|
| Hyperinsulinism | 1 | 2002 | 58 | 0.050 |
Why?
|
| Heart Valve Prosthesis | 1 | 2005 | 303 | 0.050 |
Why?
|
| Quality of Life | 2 | 2022 | 2082 | 0.050 |
Why?
|
| Brachial Artery | 1 | 2022 | 34 | 0.050 |
Why?
|
| Angiopoietin-like Proteins | 1 | 2022 | 15 | 0.050 |
Why?
|
| Azetidines | 2 | 2013 | 60 | 0.050 |
Why?
|
| Thiazoles | 1 | 2002 | 113 | 0.040 |
Why?
|
| Public Health | 1 | 2024 | 269 | 0.040 |
Why?
|
| United States Department of Defense | 1 | 2021 | 11 | 0.040 |
Why?
|
| Coronary Angiography | 2 | 2014 | 450 | 0.040 |
Why?
|
| Minority Groups | 1 | 2023 | 260 | 0.040 |
Why?
|
| Catheter Ablation | 1 | 2024 | 324 | 0.040 |
Why?
|
| Alleles | 3 | 2011 | 1673 | 0.040 |
Why?
|
| Ultrasonics | 1 | 2020 | 31 | 0.040 |
Why?
|
| Disease-Free Survival | 2 | 2013 | 905 | 0.040 |
Why?
|
| Gene Frequency | 2 | 2012 | 729 | 0.040 |
Why?
|
| Hospitals | 1 | 2023 | 435 | 0.040 |
Why?
|
| Weight Reduction Programs | 1 | 2021 | 59 | 0.040 |
Why?
|
| Syndrome | 1 | 2023 | 1155 | 0.040 |
Why?
|
| Frail Elderly | 1 | 2021 | 107 | 0.040 |
Why?
|
| Postmenopause | 1 | 2020 | 137 | 0.040 |
Why?
|
| Extracellular Space | 1 | 2019 | 79 | 0.040 |
Why?
|
| Motor Activity | 1 | 2002 | 489 | 0.040 |
Why?
|
| Patient Compliance | 1 | 2002 | 463 | 0.040 |
Why?
|
| Exercise Test | 1 | 2020 | 239 | 0.040 |
Why?
|
| Models, Statistical | 2 | 2013 | 483 | 0.040 |
Why?
|
| Surgical Wound Infection | 2 | 2012 | 267 | 0.040 |
Why?
|
| Apolipoprotein E4 | 1 | 2019 | 51 | 0.040 |
Why?
|
| Precision Medicine | 1 | 2022 | 388 | 0.040 |
Why?
|
| Observer Variation | 2 | 2014 | 311 | 0.040 |
Why?
|
| Genomics | 1 | 2007 | 1621 | 0.040 |
Why?
|
| Models, Economic | 1 | 2019 | 59 | 0.040 |
Why?
|
| Myocardial Ischemia | 1 | 2021 | 307 | 0.040 |
Why?
|
| Recurrence | 2 | 2013 | 1489 | 0.040 |
Why?
|
| Extracellular Matrix | 1 | 2019 | 232 | 0.030 |
Why?
|
| Hormone Replacement Therapy | 1 | 2021 | 187 | 0.030 |
Why?
|
| Bone Density | 1 | 2021 | 367 | 0.030 |
Why?
|
| Multicenter Studies as Topic | 1 | 2019 | 294 | 0.030 |
Why?
|
| Hospitals, Veterans | 1 | 2020 | 336 | 0.030 |
Why?
|
| Medicare | 1 | 2021 | 442 | 0.030 |
Why?
|
| Dietary Supplements | 1 | 2021 | 448 | 0.030 |
Why?
|
| Drug Administration Schedule | 2 | 2013 | 732 | 0.030 |
Why?
|
| Radiography, Thoracic | 1 | 2018 | 144 | 0.030 |
Why?
|
| Patient Readmission | 1 | 2021 | 442 | 0.030 |
Why?
|
| Costs and Cost Analysis | 1 | 2017 | 151 | 0.030 |
Why?
|
| Memory, Episodic | 1 | 2016 | 25 | 0.030 |
Why?
|
| Walk Test | 1 | 2016 | 25 | 0.030 |
Why?
|
| Survival Analysis | 2 | 2014 | 1483 | 0.030 |
Why?
|
| Hyperemia | 1 | 2016 | 30 | 0.030 |
Why?
|
| Critical Illness | 1 | 2020 | 630 | 0.030 |
Why?
|
| Limit of Detection | 1 | 2015 | 74 | 0.030 |
Why?
|
| Neuropsychological Tests | 1 | 2019 | 960 | 0.030 |
Why?
|
| Drug Utilization | 1 | 2016 | 164 | 0.030 |
Why?
|
| Independent Living | 1 | 2015 | 64 | 0.030 |
Why?
|
| Tissue Culture Techniques | 1 | 2014 | 63 | 0.030 |
Why?
|
| Multidetector Computed Tomography | 1 | 2014 | 33 | 0.030 |
Why?
|
| Blood Glucose | 1 | 2018 | 1117 | 0.030 |
Why?
|
| Phospholipases A2, Secretory | 1 | 2014 | 2 | 0.030 |
Why?
|
| Early Termination of Clinical Trials | 1 | 2014 | 17 | 0.030 |
Why?
|
| X-Ray Microtomography | 1 | 2014 | 101 | 0.030 |
Why?
|
| Biopsy, Needle | 1 | 2014 | 204 | 0.030 |
Why?
|
| Keto Acids | 1 | 2014 | 50 | 0.030 |
Why?
|
| Angina, Unstable | 1 | 2014 | 50 | 0.030 |
Why?
|
| Blood Chemical Analysis | 1 | 2014 | 79 | 0.020 |
Why?
|
| Flow Cytometry | 1 | 2016 | 765 | 0.020 |
Why?
|
| Exome | 1 | 2018 | 1061 | 0.020 |
Why?
|
| Biological Assay | 1 | 2014 | 105 | 0.020 |
Why?
|
| Estrogen Replacement Therapy | 1 | 2013 | 50 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 3 | 1 | 2013 | 89 | 0.020 |
Why?
|
| Diabetic Angiopathies | 1 | 2013 | 66 | 0.020 |
Why?
|
| Respiration Disorders | 1 | 2012 | 30 | 0.020 |
Why?
|
| Heart Injuries | 1 | 2012 | 48 | 0.020 |
Why?
|
| Elastic Modulus | 1 | 2012 | 31 | 0.020 |
Why?
|
| Discriminant Analysis | 1 | 2012 | 21 | 0.020 |
Why?
|
| Oxidoreductases, N-Demethylating | 1 | 2012 | 9 | 0.020 |
Why?
|
| Cytochrome P-450 CYP2B6 | 1 | 2012 | 13 | 0.020 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p15 | 1 | 2011 | 13 | 0.020 |
Why?
|
| HapMap Project | 1 | 2011 | 13 | 0.020 |
Why?
|
| Renal Dialysis | 2 | 2010 | 951 | 0.020 |
Why?
|
| Aryl Hydrocarbon Hydroxylases | 1 | 2012 | 40 | 0.020 |
Why?
|
| Lipoprotein Lipase | 1 | 2012 | 60 | 0.020 |
Why?
|
| Nuclear Receptor Coactivator 2 | 1 | 2012 | 147 | 0.020 |
Why?
|
| Normal Distribution | 1 | 2011 | 19 | 0.020 |
Why?
|
| Gene-Environment Interaction | 1 | 2012 | 127 | 0.020 |
Why?
|
| Anticoagulants | 1 | 2016 | 605 | 0.020 |
Why?
|
| Pattern Recognition, Automated | 1 | 2011 | 40 | 0.020 |
Why?
|
| Automation | 1 | 2011 | 65 | 0.020 |
Why?
|
| Postoperative Period | 1 | 2012 | 331 | 0.020 |
Why?
|
| Family Practice | 1 | 2011 | 84 | 0.020 |
Why?
|
| Placebo Effect | 1 | 2011 | 19 | 0.020 |
Why?
|
| Morbidity | 1 | 2012 | 256 | 0.020 |
Why?
|
| Necrosis | 1 | 2011 | 192 | 0.020 |
Why?
|
| Immunohistochemistry | 1 | 2014 | 1591 | 0.020 |
Why?
|
| Blood Specimen Collection | 1 | 2011 | 46 | 0.020 |
Why?
|
| Health Care Surveys | 1 | 2011 | 276 | 0.020 |
Why?
|
| Postoperative Hemorrhage | 1 | 2011 | 83 | 0.020 |
Why?
|
| Cells, Cultured | 1 | 2016 | 2885 | 0.020 |
Why?
|
| Internal Medicine | 1 | 2011 | 124 | 0.020 |
Why?
|
| Haplotypes | 1 | 2012 | 519 | 0.020 |
Why?
|
| Temperature | 1 | 2011 | 291 | 0.020 |
Why?
|
| Health Services Research | 1 | 2011 | 180 | 0.020 |
Why?
|
| Regression Analysis | 1 | 2012 | 761 | 0.020 |
Why?
|
| Drug Resistance | 1 | 2011 | 242 | 0.020 |
Why?
|
| Fluorescence | 1 | 2010 | 94 | 0.020 |
Why?
|
| Magnetic Resonance Angiography | 1 | 2010 | 161 | 0.020 |
Why?
|
| Genetic Loci | 1 | 2011 | 353 | 0.020 |
Why?
|
| Primary Health Care | 1 | 2016 | 775 | 0.020 |
Why?
|
| Angioplasty, Balloon | 1 | 2011 | 122 | 0.020 |
Why?
|
| Endocrinology | 1 | 2011 | 124 | 0.020 |
Why?
|
| Brain Mapping | 1 | 2011 | 384 | 0.020 |
Why?
|
| Pneumonia | 1 | 2012 | 341 | 0.020 |
Why?
|
| Community-Based Participatory Research | 1 | 2009 | 65 | 0.020 |
Why?
|
| Hemodynamics | 1 | 2012 | 810 | 0.020 |
Why?
|
| Respiratory Insufficiency | 1 | 2011 | 247 | 0.020 |
Why?
|
| Sepsis | 1 | 2012 | 493 | 0.020 |
Why?
|
| Perioperative Care | 1 | 2010 | 217 | 0.020 |
Why?
|
| Blood Platelets | 1 | 2010 | 313 | 0.020 |
Why?
|
| Heart Valve Diseases | 1 | 2007 | 162 | 0.010 |
Why?
|
| Stents | 1 | 2011 | 799 | 0.010 |
Why?
|
| Genome, Human | 1 | 2011 | 1321 | 0.010 |
Why?
|
| Creatine Kinase, MB Form | 1 | 2003 | 21 | 0.010 |
Why?
|
| Creatine Kinase | 1 | 2003 | 61 | 0.010 |
Why?
|
| Coronary Thrombosis | 1 | 2003 | 33 | 0.010 |
Why?
|
| Isoenzymes | 1 | 2003 | 211 | 0.010 |
Why?
|
| Length of Stay | 1 | 2009 | 1421 | 0.010 |
Why?
|
| Probability | 1 | 2002 | 306 | 0.010 |
Why?
|
| Disease Progression | 1 | 2007 | 2200 | 0.010 |
Why?
|
| Brain | 1 | 2011 | 3175 | 0.010 |
Why?
|
| Neoplasms | 1 | 2012 | 3016 | 0.010 |
Why?
|